Pentadeca Arginate

PDA appeared in clinic and vendor catalogues after the FDA placed BPC-157 in the restricted Category 2 compounding bucket, and it is best understood as a rebrand of the arginate salt rather than a new molecule. The peptide chain, the receptor interactions and the animal evidence base are all BPC-157's. Marketing claims that PDA is a distinct, more potent or better-absorbed compound are not supported by any published comparison. Treat any PDA-specific efficacy claim as a claim about BPC-157 until someone publishes a head-to-head.

Targets: VEGFR2, Nitric oxide / eNOS pathway, FAK-paxillin signalling

• · Some telehealth clinics prescribe considerably higher - 1000 to 2000 mcg daily - without any dose-ranging data behind it. There is no evidence the extra milligrams buy anything.

Work out your exact syringe units →

• commonInjection-site irritation
• commonProduct identity uncertainty— Because the name is a marketing label rather than a chemical one, third-party testing matters more here than for named peptides.
• uncommonHeadache

• Active malignancy - the same angiogenesis caution as BPC-157.
• Buying on the assumption it is something new - if you have already reacted badly to BPC-157, you will react the same way to this.

• redundantbpc-157 — The same peptide with a different label.
• redundantbpc-157-arginate — Chemically the same product.
• synergytb-500 — Stacked for soft tissue repair in the usual way.

• · No established bloodwork.
• · Ask for a certificate of analysis - identity is the main thing you cannot assume with a marketing-named product.

Not approved for human use. Sold by research-chemical vendors and some compounding pharmacies; the naming was itself partly a regulatory manoeuvre, and the July 2026 FDA advisory vote on BPC-157 may make the rebrand unnecessary.

• Sikiric et al., BPC 157 review series (the underlying evidence base for PDA claims) (review)
• FDA interim policy on compounding using bulk drug substances, Category 2 listings (guideline)

The honest mechanistic statement is that 'pentadeca arginate' names a commercial product rather than a molecule, and the molecule inside it is the arginate salt of BPC-157. Read the BPC-157 mechanism entry - VEGFR2 upregulation into Akt-eNOS, FAK-paxillin cytoskeletal signalling, EGR-1/NAB2, growth hormone receptor upregulation on tendon fibroblasts - because that is the entire pharmacology on offer. The name matters for one reason only. It appeared in clinic and vendor catalogues after the FDA placed BPC-157 in the restricted Category 2 compounding bucket, and it functioned as a way to keep selling the same thing. That origin is why the sequence verification flag above is set to false: not because the chemistry is doubtful in principle, but because a marketing name carries no guarantee about what is in a specific vial, and there is no reference standard for 'PDA' the way there is for a named peptide. Any claim that PDA is more potent, better absorbed or longer-acting than BPC-157 is a marketing claim with no published comparison behind it. If someone shows you a study for PDA, check the compound name in the methods section. It will say BPC 157.

The specific failure with PDA is identity. With BPC-157 you at least know what molecule the label is claiming; with a marketing name you are trusting the vendor twice - once on purity and once on what the compound even is. Get a certificate of analysis with a mass spectrum before the first injection, and check the reported mass against 1419.5 Da for the free peptide. The second failure is clinic dosing. Some telehealth practices prescribe 1000 to 2000 mcg daily, which is four to eight times the community norm, with no dose-ranging data of any kind behind it and against a rodent dose-response curve that is flat across orders of magnitude. You are paying for milligrams that the animal data says do nothing extra. The third is the belief that a prescription makes it evidence-based. A compounding pharmacy filling a PDA prescription has not run a trial. The regulatory pathway that made the name necessary is not a scientific endorsement. And the practical one: if you previously reacted badly to BPC-157, you will react the same way to this. It is not a fresh start.

• VEGFR2 (KDR) — No binding constant published

  Angiogenic cascade via receptor upregulation and Akt-eNOS signalling, inherited from BPC-157.

• eNOS / nitric oxide system — Not a receptor interaction

  Bidirectional modulation of vascular tone.

• FAK-paxillin focal adhesion complex — Not characterised

  Fibroblast migration and tendon outgrowth.

Identical to BPC-157: gut symptoms at three to seven days, connective tissue judged over two to six weeks, decision point at six weeks. Twelve-week clinic courses for chronic tendinopathy are a billing convention, not an evidence-based duration.

Do not stack this with BPC-157 or BPC-157 arginate. It is the same peptide, and the only thing that stacks is the cost. Everything else follows the BPC-157 notes: TB-500 for complementary cell migration, KPV orally for the inflammatory signal in gut work, GHK-Cu where matrix quality matters, collagen peptides plus loading for tendon substrate.

Against BPC-157 and BPC-157 arginate: chemically the same thing. Any price premium is for the name and, in the clinic channel, for the prescription and the consultation. The one honest reason to prefer a compounded PDA product over a research-chemical vial is chain of custody - a 503A pharmacy operating properly gives you better assurance about sterility and identity than an anonymous vendor. That is a real benefit and it is worth paying something for. It is just not a pharmacological benefit.

$60–$400/month. Wide range because the same peptide is sold both as a research chemical and through telehealth clinics at a large markup. Order-of-magnitude estimate only, not price-checked in the preparation of this entry.

• ?There is no reference standard or agreed definition for 'pentadeca arginate', so the sequence flag is left unverified even though the intended molecule is BPC-157 arginate.
• ?No pharmacokinetic, potency or clinical data exists for any product sold under this name.
• ?The higher clinic dose bands of 1000-2000 mcg daily have no dose-ranging basis in animals or humans.
• ?Whether the July 2026 FDA advisory committee recommendation on BPC-157 will make this rebrand commercially unnecessary is not yet resolved.
• ?Cost figures are estimates and were not price-verified in this session.

• The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration Chang CH et al., Journal of Applied Physiology, 2011 · PMID 21030672

  One of the studies routinely cited in PDA marketing. Note that it is a BPC-157 rodent study.

• BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers Mateescu DM et al., Pharmaceutics, 2026 · PMID 42198317

  The clearest statement of how little human data underpins any product in this family, whatever it is called.

• Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing McGuire FP et al., Current Reviews in Musculoskeletal Medicine, 2025 · PMID 40789979

  Useful for anyone being sold PDA by a clinic - it sets out what the musculoskeletal evidence actually is.